Sekisui To Send Staff To Xenotech And Strengthen Contract Pharmacokinetics Study Business
This article was originally published in PharmAsia News
Sekisui Medical plans to strengthen its contract pharmacokinetics studies business and new product development in the U.S. in 2009. The company will send management and staff to Kansas-based Xenotech, a U.S. in vitro drug metabolism and drug-drug interaction studies provider acquired by Sekisui last July. The company also aims to expand the U.S. and European markets for its testing drugs by establishing its own sales networks and increasing staff in the U.S. and German offices. Sekisui aims to increase overseas sales from its current 17 percent to 20 percent in 2009. (Click here for more - Japanese language
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.